Chronicle Journal: Finance

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Astellas Pharma Inc (OP: ALPMY )

16.90 USD -0.25 (-1.43%)
Streaming Delayed Price Updated: 3:54 PM EDT, Sep 27, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 62,441
Open 16.87
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 17.15
Today's Range 16.83 - 16.98
52wk Range 13.41 - 18.46
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Japan's MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
- Enfortumab vedotin is the first and only antibody-drug conjugate (ADC) approved in Japan for patients with advanced urothelial cancer - 
From PR Newswire
Astellas to Present Fezolinetant 12-Week Findings from Phase 3 SKYLIGHT 2™ Trial in Oral Session at The North American Menopause Society 2021 Annual Meeting
Astellas' investigational non-hormonal treatment demonstrates reduction in frequency and severity of moderate to severe vasomotor symptoms (VMS) associated with menopause 
From PR Newswire

Performance

YTD
+9.39%
+9.39%
1 Month
+1.08%
+1.08%
3 Month
-6.89%
-6.89%
6 Month
+8.26%
+8.26%
1 Year
+9.74%
+9.74%

More News

Read More
Astellas and MBC BioLabs Announce Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts
From PR Newswire
Astellas' and Pfizer's XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
From PR Newswire
Astellas Reports Update to September 1 Announcement on the ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
From PR Newswire
Astellas Provides Update on ASPIRO Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy
From PR Newswire
Astellas Receives European Commission Approval for First-in-Class EVRENZO™ (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease
From PR Newswire
Astellas Partners with LabCentral to Help Emerging Biotechs Accelerate Preclinical Scientific Research
From PR Newswire
Astellas Pharma's Bladder Cancer Treatment Scores Approval In Japan
Tags Benzinga Briefs ALPMF
From Benzinga
4 No-Brainer Pharmaceutical Stocks to Buy in October
Tags Stocks / Equities Pharma/Biotech Market News
From TalkMarkets
Astellas' Gene Therapy Trial Hit With Another Death, FDA Slaps Clinical Hold
Tags Health Care Market News General
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

© Copyright 2015, Chronicle Journal, Thunder Bay, ON. Powered by BLOX Content Management System from TownNews.com. [Terms of Use | Privacy Policy]